<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1E3015FF-23BB-4B73-8C80-84C53F33B745"><gtr:id>1E3015FF-23BB-4B73-8C80-84C53F33B745</gtr:id><gtr:name>Hospital for Sick Children, Toronto</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/244DB29F-915F-49C7-A968-87822A13AD3C"><gtr:id>244DB29F-915F-49C7-A968-87822A13AD3C</gtr:id><gtr:name>The Jackson Laboratory</gtr:name><gtr:address><gtr:line1>600 Main Street</gtr:line1><gtr:line2>Bar Harbor</gtr:line2><gtr:postCode>04609</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7F06A235-D83F-4EDF-A8A3-9216E21C9752"><gtr:id>7F06A235-D83F-4EDF-A8A3-9216E21C9752</gtr:id><gtr:name>Charles University</gtr:name><gtr:address><gtr:line1>Ke Karlovu 3</gtr:line1><gtr:postCode>121 16 Pra</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Czech Republic</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/19AE1042-BEA6-43F9-931B-07741962E417"><gtr:id>19AE1042-BEA6-43F9-931B-07741962E417</gtr:id><gtr:name>Central Manchester University Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/65849DDB-E500-4072-8E9D-E44749F838EE"><gtr:id>65849DDB-E500-4072-8E9D-E44749F838EE</gtr:id><gtr:name>St Vincent's Hospital</gtr:name><gtr:address><gtr:line1>St Vincent's Hospital</gtr:line1><gtr:line2>384 Victoria Street</gtr:line2><gtr:line3>Darlinghurst</gtr:line3><gtr:postCode>NSW 2010</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D9CF65B9-4220-4E2F-8AB7-9F40DD603DFF"><gtr:id>D9CF65B9-4220-4E2F-8AB7-9F40DD603DFF</gtr:id><gtr:name>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, and the Howard Hughes Research Institute, Baltimore, MD USA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/76119A17-D4F8-4258-80F0-C8B307FFFA52"><gtr:id>76119A17-D4F8-4258-80F0-C8B307FFFA52</gtr:id><gtr:name>Radboud University Nijmegen</gtr:name><gtr:address><gtr:line1>Radboud University Nijmegen</gtr:line1><gtr:line2>PO Box 9102</gtr:line2><gtr:line4>Nijmegen</gtr:line4><gtr:postCode>6500 HC</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB597297-71EC-49CA-868E-47371DFC4207"><gtr:id>CB597297-71EC-49CA-868E-47371DFC4207</gtr:id><gtr:name>Oxford Radcliffe Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1E3015FF-23BB-4B73-8C80-84C53F33B745"><gtr:id>1E3015FF-23BB-4B73-8C80-84C53F33B745</gtr:id><gtr:name>Hospital for Sick Children, Toronto</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/244DB29F-915F-49C7-A968-87822A13AD3C"><gtr:id>244DB29F-915F-49C7-A968-87822A13AD3C</gtr:id><gtr:name>The Jackson Laboratory</gtr:name><gtr:address><gtr:line1>600 Main Street</gtr:line1><gtr:line2>Bar Harbor</gtr:line2><gtr:postCode>04609</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7F06A235-D83F-4EDF-A8A3-9216E21C9752"><gtr:id>7F06A235-D83F-4EDF-A8A3-9216E21C9752</gtr:id><gtr:name>Charles University</gtr:name><gtr:address><gtr:line1>Ke Karlovu 3</gtr:line1><gtr:postCode>121 16 Pra</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Czech Republic</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/19AE1042-BEA6-43F9-931B-07741962E417"><gtr:id>19AE1042-BEA6-43F9-931B-07741962E417</gtr:id><gtr:name>Central Manchester University Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/65849DDB-E500-4072-8E9D-E44749F838EE"><gtr:id>65849DDB-E500-4072-8E9D-E44749F838EE</gtr:id><gtr:name>St Vincent's Hospital</gtr:name><gtr:address><gtr:line1>St Vincent's Hospital</gtr:line1><gtr:line2>384 Victoria Street</gtr:line2><gtr:line3>Darlinghurst</gtr:line3><gtr:postCode>NSW 2010</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D9CF65B9-4220-4E2F-8AB7-9F40DD603DFF"><gtr:id>D9CF65B9-4220-4E2F-8AB7-9F40DD603DFF</gtr:id><gtr:name>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, and the Howard Hughes Research Institute, Baltimore, MD USA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/76119A17-D4F8-4258-80F0-C8B307FFFA52"><gtr:id>76119A17-D4F8-4258-80F0-C8B307FFFA52</gtr:id><gtr:name>Radboud University Nijmegen</gtr:name><gtr:address><gtr:line1>Radboud University Nijmegen</gtr:line1><gtr:line2>PO Box 9102</gtr:line2><gtr:line4>Nijmegen</gtr:line4><gtr:postCode>6500 HC</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB597297-71EC-49CA-868E-47371DFC4207"><gtr:id>CB597297-71EC-49CA-868E-47371DFC4207</gtr:id><gtr:name>Oxford Radcliffe Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FEF0C22B-9F9C-499B-AA97-A8A565201F62"><gtr:id>FEF0C22B-9F9C-499B-AA97-A8A565201F62</gtr:id><gtr:firstName>Caleb</gtr:firstName><gtr:surname>Webber</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B742EBC0-45FE-4A15-AD54-A9726F252787"><gtr:id>B742EBC0-45FE-4A15-AD54-A9726F252787</gtr:id><gtr:firstName>Christoffer</gtr:firstName><gtr:surname>Nellaker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8F8C28F1-22C4-4E4D-935B-A431D732F5B8"><gtr:id>8F8C28F1-22C4-4E4D-935B-A431D732F5B8</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Ponting</gtr:surname><gtr:orcidId>0000-0003-0202-7816</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6DB33BF0-3EA1-420D-9875-85B72E852F6A"><gtr:id>6DB33BF0-3EA1-420D-9875-85B72E852F6A</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Zisserman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FM01326X%2F1"><gtr:id>29131BB6-6E52-4BD8-AC21-B9CBFAC99484</gtr:id><gtr:title>Automated phenotyping to accurately infer functional variants in clinical genetics</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M01326X/1</gtr:grantReference><gtr:abstractText>Rare diseases are numerous - so much so that as a group they are very common. One person in 17 has a rare genetic disorder, but most fail to receive a genetic diagnosis. Diagnosing the genetic cause of a disorder, even when there are only a handful of cases in the world, represents the first of many steps in finding effective treatments. Even though new genetic tests promise to assist in diagnosing some of these patients, the tests are expensive and currently only available to a few people in the wealthiest countries.

For the past 65 years expert clinical doctors have been matching a diagnosis to patients based on facial features and follow up clinical tests. We are developing algorithms through which a computer will learn and apply these skills objectively. 

Identifying patients with the same genetic disorders allows comparisons to be made between them. In turn, this can improve estimates of how the disease might progress and allow direct therapeutic benefits, for instance by showing which symptoms are caused by the genetic disorder and which symptoms might be caused by other clinical issues that can be treated.

Using the latest research in computer vision and machine learning the algorithm automatically analyses patient photographs and finds their place in &amp;quot;Clinical Face Phenotype Space&amp;quot; (CFPS). Patients that share a specific dysmorphic disease or syndrome, will cluster together in CFPS. The CFPS model is created and shaped using ordinary, family album photos and accounts for variations between images that are not disease relevant (such as lighting, image quality, background, pose, age, gender, ethnicity, and facial expression).

In the present application we seek funding to develop methods for clinical geneticists to query CFPS for clinically relevant information. The work will develop means by which a patient's similarity to other patient groups can be visualised, explored and tested through robust statistical modelling. 

Furthermore we will make it possible to overlay a patient's DNA with CFPS to identify disease causing mutations. This will improve our understanding of how rare diseases disrupt the normal functioning of the body, and in turn influence decisions in treatment strategies.

A clinician should, in future, be able to take a smartphone picture of a patient and query CFPS to quickly find out which genetic disease the person might have. For diseases unknown to medical science, CFPS will find if there are any other patients around the world that might have the same disease.

CFPS will learn from our faces to help diagnose rare diseases.</gtr:abstractText><gtr:technicalSummary>We will pursue three primary methodological approaches required to allow us to leverage CFPS together with genotype data to aid clinical diagnoses. 
1. Develop methods to allow clinicians to explore and interpret data in CFPS. 
We will build on the foundation of the CFPS pipeline to return clinically meaningful data interpretations. This will require a 2nn based and Bayesian Risk framework for estimating the probability that two faces show similarity. Using dimensionality reduction approaches such as Stochastic Neighbour Embedding we will create navigation and visualisation software to explore informative vectors in CFPS. We will develop a likelihood based method for assessing consistency within groups to detect endophenotype stratification within syndromes.

2. Infer causative genotype-phenotype associations by integrating functional gene networks within the CFPS. 
Next, we will develop methods to integrate DNA variation into CFPS. This will allow the automatic analysis of craniofacial phenotypes to predict the likelihood of functional pathways being causally disrupted in syndromes. We will use functional genetic pathway information to improve the predictive power of CFPS for clinical genetics and, vice versa, we will also use CFPS to enhance the power of functional gene networks in computational biology. To explore relationships between facial similarities (CFPS) and gene functional similarities we will use machine learning to alter the structure of informative vectors in CFPS to create a honed Functional Genetic CFPS (fgCFPS).

3. Create a robust statistical framework to infer perturbations in functional genetic pathways from facial phenotypes.
Finally, we will develop methods for querying fgCFPS to aid the understanding of complex genetic disorders with unknown aetiology. From the new fgCFPS we will develop methods that assign likelihood estimates for the contributions of functional pathways to syndromes where causative genetics are unknown or complex.</gtr:technicalSummary><gtr:potentialImpactText>This project is highly collaborative both within the UK and internationally. This is also translational and interdisciplinary science, criss+crossing the fields of computer vision, computational biology, and clinical genetics. Consequently it provides several direct pathways to impact. The most important of these is that our work will aid in the clinical diagnosis worldwide of the genetics of rare disorders. We have established and will be expanding an international network of collaborations to apply and develop our approach using patient data. We expect this project in 3 years' time to have progressed to being in the early stages of implementation in clinical genetics counselling, initially in the UK and Europe and then elsewhere. 

In the space of three years the following directions will lead to measurable impacts:

The methods to interrogate CFPS together with genotype will add statistical power to the inference of genetic diagnoses. In collaboration with clinical sequencing efforts our approach will be applied to patient image data to add value to these existing datasets and on-going projects. This will result in research participants receiving diagnoses that otherwise they would not. 

As part of the larger research effort we will set up partnerships with patient support groups for syndromes with identified genetic origins. We will present the science and the project as a means of public engagement, and offer the opportunity to contribute photos (under an informed consent model) for the further refinement of the CFPS. This is public engagement of the best and most interactive kind, which can be measured by the number of images of individuals (&amp;gt;10,000) and syndromes (&amp;gt;200) that we hope to collect over the coming years.

We will expand collaborations to additional clinical geneticists across the world. For clinicians the practical utility would be to evaluate the approach as a means of narrowing down hypotheses for the clinical diagnosis of known syndromes. Their results will also directly feed back to the project, as they will expand the number of images of clinically defined syndromes that will iteratively improve the CFPS - the more people that use it the better it gets. 

We anticipate that extending contacts within the MRC Units in The Gambia and Uganda would be a beneficial means of geographically widening our research to efficiently test and apply CFPS in the future.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-06-05</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>319522</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital (GOSH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>CDDB37E8-8D5A-4D48-988F-B2E617FF675E</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford Radcliffe Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>0F54ADB1-9EB9-4B91-9892-7F53BFB170CC</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>5F627A37-2B85-4F28-95D0-BD8F0B89BD61</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Melbourne</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Murdoch Children's Research Centre</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>332A731D-F343-41EA-AEDC-A8DEF78EC071</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Jackson Laboratory</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>DB127C98-D723-46AC-8764-1CC5DFDFAC55</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charles University</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:department>School of Medicine Charles Prague</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>EFC96716-BFF9-48D8-BD16-AB01365FD19D</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>859FF75E-EEA2-4397-AE29-A7FFD0803C8E</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital for Sick Children, Toronto</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>FFE0949F-726B-42EB-B03B-191EB70BF186</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baylor College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>89EC4CE9-F7A7-4FEF-AA3F-13CD64ABE686</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>CEE09623-C789-4044-91C2-9BE0ED9558FC</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central Manchester University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>32466A65-F8D0-4926-A5C0-73D47D031F19</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>A1446630-BEC8-41DD-BB94-5AD633C692F2</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>University Medical Center Nijmegen</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>E00AF0AB-239A-4C6C-94CE-7B39EB9FFA57</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Freeman Hospital</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>E3BDA257-F113-4A90-AF98-D7C5698F38E8</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, and the Howard Hughes Research Institute, Baltimore, MD USA</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>834158DD-5149-4865-B3E8-100638918E32</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>1C9A6E52-9B80-4790-ACB6-B674C1781BFB</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Vincent's Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>The Garvan Institute for Medical Research</gtr:department><gtr:description>Minerva Consortium</gtr:description><gtr:id>817957FB-5918-4D41-8385-C6FC5F29070A</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oregon Health and Science University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>1D3C168C-6D13-4EF9-AB75-8B7DF9CCFA9D</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Minerva Consortium</gtr:description><gtr:id>EF06215B-226C-4953-8128-C2166A81C2D4</gtr:id><gtr:impact>Newly launched, no outputs yet.</gtr:impact><gtr:partnerContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:partnerContribution><gtr:piContribution>We launched the Minerva Consortium at the start of 2017 to enable the development of computational phenotyping from clinical imaging, specifically to aid the diagnosis of rare and developmental diseases. The MC structure is intended to coordinate research efforts and patient data sets for projects in an open academic collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MR/M01326X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>12A0B409-0C29-4056-9092-2D86E44017F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.4  Methodologies and measurements</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>